The collaboration with LEO Pharma will be mutually beneficial, creating a strong partnership that allows Antares to team up with and derive benefit from a successful commercial organization, while LEO Pharma expands its portfolio with a new product in its field of expertise.
LEO Pharma has a dedicated sales force of 75 representatives in the United States that are focused exclusively on treating psoriasis, making the company a viable entity for introducing and establishing OTREXUP as a valuable new treatment option with significant growth potential in dermatology. LEO’s sales force will complement Antares’ own dedicated sales representatives, who are detailing OTREXUP for rheumatoid arthritis.
“We are excited to launch and promote OTREXUP to dermatologists as an important new treatment option for psoriasis patients, and we look forward to working with our partner, Antares, to provide the necessary service, knowledge and expertise to successfully introduce OTREXUP,” said LEO Pharma A/S Executive Vice President Lars Olsen. “As a global leader in the treatment of psoriasis, we have continually offered innovative and novel treatment solutions to patients. The ease of use and improved bioavailability that OTREXUP delivers will expand our current portfolio of products for the treatment of psoriasis and help LEO Pharma continue to realize its vision of being the world’s leading dermatology specialty pharmaceutical company.”
For more information about Antares Pharma, visit www.antarespharma.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
